Novel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance

• Published in: Molecular and cellular biology Vol. 36; no. 16; pp. 2168 - 2181
• Main Authors: Popineau, Lucie, Morzyglod, Lucille, Carré, Nadège, Caüzac, Michèle, Bossard, Pascale, Prip-Buus, Carina, Lenoir, Véronique, Ragazzon, Bruno, Fauveau, Véronique, Robert, Lorenne, Guilmeau, Sandra, Postic, Catherine, Komatsu, Masaaki, Canonne-Hergaux, François, Guillou, Hervé, Burnol, Anne-Françoise
• Format: Journal Article
• Language: English
• Published: American Society for Microbiology 01.08.2016
• Subjects: Cellular Biology; Life Sciences
• ISSN: 0270-7306; 1098-5549
• DOI: 10.1128/MCB.00170-16

A long-standing paradox in the pathophysiology of metabolic diseases is the selective insulin resistance of the liver. It is characterized by a blunted action of insulin to reduce glucose production, contributing to hyperglycemia, while de novo lipogenesis remains insulin sensitive, participating in turn to hepatic steatosis onset. The underlying molecular bases of this conundrum are not yet fully understood. Here, we established a model of selective insulin resistance in mice by silencing an inhibitor of insulin receptor catalytic activity, the growth factor receptor binding protein 14 (Grb14) in liver. Indeed, Grb14 knockdown enhanced hepatic insulin signaling but also dramatically inhibited de novo fatty acid synthesis. In the liver of obese and insulin-resistant mice, downregulation of Grb14 markedly decreased blood glucose and improved liver steatosis. Mechanistic analyses showed that upon Grb14 knockdown, the release of p62/sqstm1, a partner of Grb14, activated the transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2), which in turn repressed the lipogenic nuclear liver X receptor (LXR). Our study reveals that Grb14 acts as a new signaling node that regulates lipogenesis and modulates insulin sensitivity in the liver by acting at a crossroad between the insulin receptor and the p62-Nrf2-LXR signaling pathways.